Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 14/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CD69 | Q07108 | 6/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21270515 | 1.00 | ALDH1A1 (0.46) | ALDH1A1TSHRHTTNPSR1BTK | |
| SCHEMBL21270663 | 0.91 | ALDH1A1 (0.43) | ALDH1A1TSHRHTTNPSR1BTK | |
| SCHEMBL30008498 | 0.91 | ALDH1A1 (0.43) | ALDH1A1TSHRHTTNPSR1BTK | |
| Aficamten SCHEMBL30167980 | 0.91 | BTK (0.44) | ALDH1A1TSHRHTTNPSR1BTK | |
| Aficamten SCHEMBL21179170 | 0.91 | BTK (0.44) | ALDH1A1TSHRHTTNPSR1BTK | |
| Aficamten SCHEMBL21179172 | 0.91 | BTK (0.44) | ALDH1A1TSHRHTTNPSR1BTK | |
| SCHEMBL21270370 | 0.90 | ALDH1A1 (0.45) | ALDH1A1TSHRHTTNPSR1BTK | |
| SCHEMBL30009124 | 0.89 | SIRT2 (0.42) | ALDH1A1TSHRHTTNPSR1BTK | |
| SCHEMBL21270372 | 0.89 | SIRT2 (0.42) | ALDH1A1TSHRHTTNPSR1BTK | |
| SCHEMBL21270353 | 0.89 | WDR5 (0.42) | ALDH1A1TSHRHTTNPSR1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740481-B9 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2024-10-23 | — | — | EP | claimed |
| EP-3740481-B1 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2024-06-26 | — | — | EP | claimed |
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-02-20 | — | — | US | disclosed |
| US-12065436-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20230119665-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11472796-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119665-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885 |
| US-12065436-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885 |
| US-11472796-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885 |
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | ALDH1A1 3390/4885TSHR 2655/4885HTT 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.